A recent nationwide study in India delivered a powerful message: every single one of 131 generic medicine samples, spanning 22 essential categories, met all quality criteria. Crucially, these life-saving drugs cost significantly less than their branded counterparts. The quality and affordability of these generic drugs offer tangible assurance for millions seeking affordable healthcare, proving that access to vital medicines need not be a financial burden.
Yet, despite generics being chemically and therapeutically equivalent to branded drugs, and offering massive cost savings, public perception and market penetration often lag behind their demonstrated value. Consumers, even in 2026, still question their trustworthiness, despite extensive testing.
Increased public awareness and robust policy support for generic drug adoption appear poised to drive substantial healthcare cost reductions and improve access to essential medicines globally.
Quality Confirmed: Generics Match Brands on Efficacy
The Mission for Ethics & Science in Healthcare (MESH) study, reported by The Week, meticulously analyzed 131 samples across 22 categories of essential medicines. Every single generic drug tested met all quality criteria, mirroring their branded counterparts.
The cost disparity is stark: a branded medicine tablet averaged Rs 11.17, while local generics cost Rs 5.74, and Jan Aushadhi medicines a mere Rs 2.40 per tablet, according to The Week. The stark cost disparity, with branded medicine tablets averaging Rs 11.17 compared to local generics at Rs 5.74 and Jan Aushadhi medicines at Rs 2.40 per tablet, confirms that patients can trust generic medicines for their quality, while immediately benefiting from substantial price differences.
The Steep Drop: How Generics Drive Down Drug Prices
Upon patent expiry, the price of unbranded drugs can drop by almost 50% compared to branded drugs, according to pmc. The almost 50% drop in price of unbranded drugs upon patent expiry immediately opens the door for intense market competition.
